Sustainable Development Center 

  • O‘zbek
  • Ўзбек
  • Русский
  • English
  • Français

Seven-minute cholesterol testing in pharmacies: lessons from Еngland and implications for Uzbekistan

19-11-2026 174

    Early identification of cardiovascular risk factors is essential to prevention, as it creates opportunities for intervention before disease progresses. According to the National Statistics Committee of Uzbekistan, diseases of the circulatory system caused more than 100,000 deaths in the country in 2025. Raised blood pressure, elevated cholesterol, smoking, physical inactivity and unhealthy dietary habits increase cardiovascular risk. Elevated cholesterol is often asymptomatic, making early detection particularly important.

    A pilot initiative in England explored the potential of community pharmacies to make preventive screening more accessible. Delivered in partnership by Barts Health NHS Trust, UCLPartners and HEART UK, the initiative involved specially trained pharmacists in rapid cholesterol testing and preliminary cardiovascular risk assessment.

    A small finger-prick blood sample is analysed using a point-of-care device, with the cholesterol measurement taking up to seven minutes. This time frame refers to the measurement itself, not to the full clinical assessment. The result is considered alongside the individual’s age, blood pressure and other risk factors to estimate their ten-year risk of myocardial infarction or stroke. Where appropriate, individuals are given advice on lifestyle changes or referred to a doctor.

    Between January 2025 and March 2026, 2,493 people received the service across 61 pharmacies. For 19% of those tested, further clinical assessment was considered necessary to determine whether medication was appropriate; 88 people began statin treatment. Following the pilot, plans were announced to extend the initiative to approximately 100 additional pharmacies across England from autumn 2026. Although the service is free of charge, it is restricted to individuals who meet specified eligibility criteria.

    The significance of this approach extends beyond the speed of testing. Equally important is the continuity of care after screening: identifying risk, communicating findings, arranging appropriate clinical referrals and ensuring follow-up. The model used in England, however, cannot be transferred unchanged to another country. Pharmacists’ scope of practice, medical data protection requirements, equipment quality assurance and referral pathways would all need to comply with the relevant national legislation.

    Uzbekistan already has an institutional basis for piloting a comparable approach. Presidential Resolution No. PQ-20 of 20 January 2026 provides for the phased implementation of the National Programme to Combat Heart Attacks and Strokes. It calls for targeted cardiovascular risk screening among people over the age of 30, with initial implementation scheduled to begin in Samarkand Region and Tashkent on 1 May 2026.

    Ongoing reforms in Samarkand Region provide a further opportunity to examine this approach. On 17 November 2026, the World Bank approved a US$100 million concessional credit for SHIFO-1, a programme aimed at strengthening primary healthcare in the region. Planned activities include cardiovascular risk screening for 330,000 adults and treatment monitoring for 250,000 patients. The World Bank’s official announcement does not identify pharmacy-based cholesterol testing as a separate component. Nevertheless, such testing could be piloted as a complement to existing preventive services.

    Subject to appropriate medical and legal review, a six-month pilot involving 20–30 pharmacies in urban and remote areas of Samarkand Region is proposed. A funding mechanism should be established in advance to ensure that testing is free of charge for participants. Pharmacists would require specialised training, and testing devices would need routine quality control. Clear procedures should also be developed for referring individuals at elevated risk to a family doctor, arranging confirmatory laboratory tests where necessary and ensuring secure exchange of medical data.

    The number of tests performed would not, on its own, provide an adequate measure of the pilot’s effectiveness. Evaluation should examine the number of people in whom previously unrecognised risk factors are detected, the number of referred individuals who attend a medical consultation, the number who begin treatment or enter preventive follow-up, and the cost of identifying each person at elevated risk. These indicators would support evidence-based decisions on whether to extend the approach to other regions.

    The proposal aligns with United Nations Sustainable Development Goal 3, particularly Target 3.4 on reducing premature mortality from non-communicable diseases and Target 3.8 on universal health coverage, including access to quality essential health services. It also complements the priorities of the Uzbekistan 2030 Strategy concerning the promotion of healthy lifestyles. Nevertheless, cholesterol testing should be regarded as only one component of comprehensive prevention.

    Experience in England suggests that community pharmacies can improve access to preventive services. In Uzbekistan, closer coordination among pharmacies, family medicine clinics and digital health systems could make rapid cholesterol testing an additional means of identifying cardiovascular risk at an early stage.

Alisher Azizov

Chief Specialist, Centre for Sustainable Development